, Volume 66, Issue 3, pp 494–502 | Cite as

Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice

  • Sha Sha
  • Xiaoming Liu
  • Ruxing Zhao
  • Li Qing
  • Qin He
  • Lei SunEmail author
  • Li ChenEmail author
Original Article



Metabolic syndrome is a chronic-metabolic disease caused by a variety of factors, including high peripheral blood insulin levels and insulin resistance. It has been reported that GLP-1 could regulate insulin resistance. It is not known whether and how GLP-1 protects from fat-induced inflammation and immune changes. We investigated if GLP-1 alters the populations of fat-induced inflammation and immune cells and the related mechanism.


We obtained obese C57BL/6J mice by feeding them high-fat food, then treated the obese mice with GLP-1+ high-fat diet (G + Hi), normal chow diet (Nor), or high-fat diet (Hi) (n = 20 for each group) for 8 weeks. The GLP-1 receptor−/− B6 group were fed with HFD for 8 weeks (GLP-1R KO + Hi). In vivo and in vitro experiments were conducted on mice immune cells to investigate the effects of GLP-1 on the changes of the immune components and functions in obesity.


We found that GLP-1 could efficiently change the CD4+ T subsets and level of cytokines in high-fat-induced mice by GLP-1 receptor. Further, these changes were correlated with a reduction in fat content and serum lipid level. Interestingly, GLP-1 could enhance the function of Tregs in vitro.


Our data showed that GLP-1 has an important role in shaping the CD4+ T population in high-fat-diet-induced mice by GLP-1 receptor, possibly providing a new target for the treatment of metabolic syndrome.


Obesity Immune GLP-1 Metabolic syndrome 



This work was supported by grants from the Key Research and Development Program of Shandong Province (No. 2016GSF201012) and the Natural Science Foundation of Shandong Province (No. BS2015YY011) and the National Natural Science Foundation (No. 81500631).

Authors' contributions

LS conceived the project. SS and LS designed the experiments. SS analyzed the data and conducted experiments. SS wrote and edited the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.


  1. 1.
    M.A. Nauck, J.J. Meier, Incretin hormones: their role in health and disease. Diabetes Obes. Metabol. 20(Suppl 1), 5–21 (2018)CrossRefGoogle Scholar
  2. 2.
    S.K. Tasci, S.A. Bingol, GLP-1 localisation and proglucagon gene expression in healthy and diabetic mouse ileum. J. Vet. Res. 62(2), 237–242 (2018)CrossRefGoogle Scholar
  3. 3.
    A. Itoh, J. Irie, H. Tagawa et al. GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice. J. Diabetes Complicat. 31(9), 1370–1375 (2017)CrossRefGoogle Scholar
  4. 4.
    G.S. Carls, E. Tuttle, R.D. Tan et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care 40(11), 1469–1478 (2017)CrossRefGoogle Scholar
  5. 5.
    E. Grasset, A. Puel, J. Charpentier et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell Metabol. 26(1), 278 (2017)CrossRefGoogle Scholar
  6. 6.
    Q. Li, Y. Lin, S. Wang et al. GLP-1 inhibits high-glucose-induced oxidative injury of vascular endothelial Cells. Sci. Rep. 7(1), 8008 (2017)CrossRefGoogle Scholar
  7. 7.
    J.P. Mayer, M.H. Tschop, R.D. DiMarchi, Once blind, now we see GLP-1 molecular action. Cell Metabol. 26(2), 289–291 (2017)CrossRefGoogle Scholar
  8. 8.
    D.N. McBrayer, Y. Tal-Gan, Recent advances in GLP-1 receptor agonists for use in diabetes mellitus. Drug Dev. Res. 78(6), 292–299 (2017)CrossRefGoogle Scholar
  9. 9.
    E. Adams, P. Genter, E. Keefe et al. The GLP-1 response to glucose does not mediate beta and alpha cell dysfunction in Hispanics with abnormal glucose metabolism. Diabetes Res Clin. Pract. 135, 185–191 (2018)CrossRefGoogle Scholar
  10. 10.
    C.S. Bae, J. Song, The role of glucagon-like peptide 1 (GLP1) in type 3 diabetes: GLP-1 controls insulin resistance, neuroin-flammation and neurogenesis in the brain. Int. J. Mol. Sci. 18(11), 2493 (2017)CrossRefGoogle Scholar
  11. 11.
    L.L. Baggio, J.R. Ussher, B.A. McLean et al. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Mol. Metabol. 6(11), 1339–1349 (2017)CrossRefGoogle Scholar
  12. 12.
    D.A. Briere, A.B. Bueno, E.J. Gunn et al. Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery. Diabetes 67(2), 309–320 (2018)CrossRefGoogle Scholar
  13. 13.
    R. Caiazzo, J. Branche, M. Daoudi et al. Increased postprandial glucagon-like peptide-1 (GLP-1) production after endoscopic gastrointestinal bypass using the Cousin lumen-apposing stent in a porcine model. Endoscopy 50(1), 14–21 (2018)PubMedGoogle Scholar
  14. 14.
    M.A. Sanchez-Garrido, S.J. Brandt, C. Clemmensen et al. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia 60(10), 1851–1861 (2017)CrossRefGoogle Scholar
  15. 15.
    U. Anyanwagu, U. Anyanwagu, J. Mamza, R. Donnelly, I. Idris, Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: a large retrospective UK cohort study. Am. Heart J. 196, 18–27 (2018)CrossRefGoogle Scholar
  16. 16.
    X. Cai, J. Li, M. Wang et al. GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1/2-HDAC6 signaling pathway. Int J. Med Sci. 14(12), 1203–1212 (2017)CrossRefGoogle Scholar
  17. 17.
    P. Almgren, A. Lindqvist, U. Krus, et al. Genetic determinants of circulating GIP and GLP-1 concentrations. JCI Insight. 2(21), e93306 (2017)Google Scholar
  18. 18.
    D. Athauda, T. Foltynie, Protective effects of the GLP-1 mimetic exendin-4 in Parkinson’s disease. Neuropharmacology 136(Pt B), 260–270 (2018)CrossRefGoogle Scholar
  19. 19.
    S. Baba, M. Iwasa, K. Higashi et al. Antidiabetic drug alogliptin protects the heart against ischemia-reperfusion injury through GLP-1 receptor-dependent and receptor-independent pathways involving nitric oxide production in rabbits. J. Cardiovasc. Pharmacol. 70(6), 382–389 (2017)PubMedGoogle Scholar
  20. 20.
    K. Coveleskie, L.A. Kilpatrick, A. Gupta et al. The effect of the GLP-1 analogue exenatide on functional connectivity within an NTS-based network in women with and without obesity. Obes. Sci. Pract. 3(4), 434–445 (2017)CrossRefGoogle Scholar
  21. 21.
    H.M. Dorton, S. Luo, J.R. Monterosso, K.A. Page, Influences of dietary added sugar consumption on striatal food-cue reactivity and postprandial GLP-1 response. Front. Psychiatry 8, 297 (2017)CrossRefGoogle Scholar
  22. 22.
    R. Garg, Nutritional insulin or Glp-1 receptor agonist: crossroads in the treatment of type 2 diabetes mellitus. Endocr. Pract. 23(11), 1357–1358 (2017)CrossRefGoogle Scholar
  23. 23.
    C. Giezenaar, N.D. Luscombe-Marsh, A.T. Hutchison, et al., Effect of age on blood glucose and plasma insulin, glucagon, ghrelin, CCK, GIP, and GLP-1 responses to whey protein ingestion. Nutrients 10(1), 2 (2017)CrossRefGoogle Scholar
  24. 24.
    A. Leonardini, R. D’Oria, M.A. Incalza et al. GLP-1 receptor activation inhibits palmitate-induced apoptosis via ceramide in human cardiac progenitor cells. J. Clin. Endocrinol. Metabol. 102(11), 4136–4147 (2017)CrossRefGoogle Scholar
  25. 25.
    X. Wang, J. Liu, C. Li, et al., Impaired secretion of active GLP-1 in patients with hypertriglyceridaemia: a novel lipotoxicity paradigm? Diabetes Metabol. Res. Rev. 34(2), e2964 (2018)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of EndocrinologyQilu Hospital of Shandong UniversityJinanChina
  2. 2.Institute of Endocrine and Metabolic Diseases of Shandong UniversityJinanChina
  3. 3.Key Laboratory of Endocrine and Metabolic DiseasesShandong Province medicine& healthJinanChina

Personalised recommendations